Haleon Turns to Weight-Loss Drug Users for its Next U.S. Growth Opportunity
Haleon (NYSE:HLN) targets U.S. growth by addressing GLP-1 drug side effects, seeing a 24% sales increase in CVS stores. North America showed Q2 2026 organic revenue growth of 3.1%. The strategy focuses on Advil and Digestive Health products, with potential expansion to Walmart and Target. Haleon's 2025 North American revenue was £3.87 billion, with a 0.4% decline. The company aims to leverage GLP-1 trends to boost U.S. performance.
How this was made
The 30-second read
Why it matters
The strategy could modestly improve Haleon's U.S. sales if expanded beyond pilot stores.
Market read
A niche growth initiative with limited immediate market impact but potential for incremental upside.
What to watch
Consumer adoption of GLP‑1 drugs could plateau, limiting the addressable market.
Background
Haleon is seeking growth in North America after a weak 2025 performance, leveraging GLP‑1 drug usage trends.
Ticker impact
Haleon reported a 24% sales increase per CVS store after placing GLP-1 side‑effect products, indicating a new growth driver in the U.S. OTC market.
Limited short‑term price move; potential gradual upside if rollout expands.
The per‑store uplift is promising but confined to a subset of stores; broader impact on revenue remains uncertain.
Market effects
May encourage other consumer‑health firms to pursue similar shelf‑placement strategies.
Potential boost for U.S. OTC market participants.
Limited, primarily U.S. focused.
Counterpoint
The uplift may be a short‑lived promotional effect that won't translate into sustained revenue growth.
Key entities
- companyHaleon plc
Consumer‑health company implementing GLP‑1 side‑effect product placement.
- retailerCVS
Retail partner where Haleon piloted the merchandising approach.
